Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
The platform’s technology works as a compression algorithm for molecular testing
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
Subscribe To Our Newsletter & Stay Updated
